BioSpace News Archive

According to Vision Research Reports, the global Oncology Information Systems market size is expected to be worth around US$ 4.4 billion by 2030 from valued at US$ 2.66 billion in 2020 and is anticipated to grow at a CAGR of 9.4% from 2021 to 2030.

A recent report provides crucial insights along with application based and forecast information in the Global Scar Treatment Product Market.

A recent report provides crucial insights along with application based and forecast information in the Global Prasugrel Hydrochloride Market.

ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors.

Galapagos NV (Euronext & NASDAQ: GLPG), CellPoint and AboundBiotoday announced that both companies have entered into definitive agreements with Galapagos, propelling Galapagosinto next-generation cell therapywhile significantly broadening itsportfolio and capabilities.

Aeterna Zentaris Inc. announced that all items of business, other than the proposed consolidation of the Company’s shares, were approved at its annual meeting of shareholders held today.

Numinus Wellness Inc. (“Numinus”) (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 1st Annual Mental Health Conference to be held at the Lotte New York Palace Hotel in New York City on Monday, June 27, 2022.

ICON plc, a world-leading healthcare intelligence and clinical research organisation, announced that it will release its financial results for the second quarter 2022 after the market closes on Wednesday, July 27, 2022.

Danaher Corporation announced that it will webcast its quarterly earnings conference call for the second quarter 2022 on Thursday, July 21, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further advancement in its fully-funded, multi-center Phase 2 clinical trial of lead drug candidate MYMD-1® as a therapy for delaying aging and expanding healthy lifespan.